United Therapeutics Corporation $UTHR Shares Purchased by Aurora Investment Counsel

Aurora Investment Counsel increased its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 8.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,134 shares of the biotechnology company’s stock after acquiring an additional 549 shares during the quarter. Aurora Investment Counsel’s holdings in United Therapeutics were worth $2,050,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. XTX Topco Ltd acquired a new stake in United Therapeutics during the first quarter worth about $313,000. Allianz Asset Management GmbH raised its stake in United Therapeutics by 96.9% during the first quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock worth $20,832,000 after acquiring an additional 33,254 shares during the period. LPL Financial LLC raised its stake in United Therapeutics by 77.3% during the first quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock worth $7,783,000 after acquiring an additional 11,007 shares during the period. CWM LLC raised its stake in United Therapeutics by 204.3% during the second quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock worth $1,492,000 after acquiring an additional 3,487 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in United Therapeutics by 11.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company’s stock worth $1,129,000 after acquiring an additional 376 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. UBS Group increased their price objective on shares of United Therapeutics from $560.00 to $580.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Morgan Stanley increased their price objective on shares of United Therapeutics from $328.00 to $435.00 and gave the stock an “equal weight” rating in a research note on Friday, October 10th. Bank of America raised their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Royal Bank Of Canada started coverage on shares of United Therapeutics in a research note on Friday, September 26th. They issued an “outperform” rating and a $569.00 price target on the stock. Finally, HC Wainwright raised their price target on shares of United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a research note on Friday, September 5th. Nine equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $461.62.

Insider Activity at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total value of $9,396,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total transaction of $3,396,250.00. Following the completion of the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at $11,356,133.75. This trade represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 307,435 shares of company stock valued at $125,401,167 over the last quarter. Insiders own 10.30% of the company’s stock.

United Therapeutics Trading Down 0.1%

Shares of NASDAQ:UTHR opened at $432.69 on Tuesday. The firm’s 50 day moving average is $388.34 and its two-hundred day moving average is $329.17. The firm has a market capitalization of $19.52 billion, a P/E ratio of 16.89, a PEG ratio of 4.72 and a beta of 0.66. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $459.48.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company’s revenue was up 11.7% on a year-over-year basis. During the same quarter last year, the business earned $5.85 earnings per share. Analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.